Review
Oncology
Devindee Nugawela, Kylie L. Gorringe
Summary: This narrative review explores the current evidence for targeted therapies in mucinous ovarian carcinoma. A total of 21 studies were included in the review, identifying 11 different targeted therapies. Further investigation and combination with other treatments are warranted for these therapies.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Biochemistry & Molecular Biology
Zhi-Bing You, Eliot L. Gardner, Ewa Galaj, Allamar R. Moore, Tristram Buck, Chloe J. Jordan, Bree A. Humburg, Guo-Hua Bi, Zheng-Xiong Xi, Lorenzo Leggio
Summary: The study found that the use of oxycodone can increase ghrelin levels and upregulate GHS-R1a mRNA levels, leading to increased drug reward. Pretreatment with the antagonist JMV2959 can reduce oxycodone self-administration, indicating the importance of the ghrelin system in oxycodone use.
MOLECULAR PSYCHIATRY
(2022)
Review
Immunology
Ibrar Muhammad Khan, Safir Ullah Khan, Hari Siva Sai Sala, Munir Ullah Khan, Muhammad Azhar Ud Din, Samiullah Khan, Syed Shams ul Hassan, Nazir Muhammad Khan, Yong Liu
Summary: The tumor microenvironment plays a crucial role in the development, metastasis, and response to therapy of tumors. By studying the pathogenesis, changes in the microenvironment, and new treatment methods of brain metastases, the paper reveals the development rules and key driving factors of the disease, and promotes the clinical precision medicine of brain metastases.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
David J. Benjamin, Robert Hsu
Summary: The treatment of metastatic urothelial carcinoma has undergone significant changes over the past decade, with the approval of various therapies such as immune checkpoint inhibitors, targeted therapies, and antibody drug conjugates. Despite the identification of multiple recurring mutations through next generation sequencing, only one targeted therapy has been developed and approved so far. Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) inhibitor, has shown effectiveness in treating FGFR-altered urothelial carcinoma, especially when combined with immunotherapy. Ongoing trials are evaluating the use of erdafitinib in different settings and exploring other FGFR targeted agents.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Medicinal
Yagmur Sisman, Lau Kraesing Vestergaard, Douglas Nogueira Perez de Oliveira, Tim Svenstrup Poulsen, Tine Henrichsen Schnack, Claus Hogdall, Estrid Hogdall
Summary: This study analyzed the mutational profile of 128 Danish patients with high-grade serous ovarian cancer and found PARP inhibitors to be the most frequent potential targeted therapy, while indicating the relevance of investigating other targeted therapies based on mutational findings.
Article
Genetics & Heredity
Sirui Zhou, Olukayode A. Sosina, Jonas Bovijn, Laetitia Laurent, Vasundhara Sharma, Parsa Akbari, Vincenzo Forgetta, Lai Jiang, Jack A. Kosmicki, Nilanjana Banerjee, John A. Morris, Erin Oerton, Marcus Jones, Michelle G. LeBlanc, Vincent Idone, John D. Overton, Jeffrey G. Reid, Michael Cantor, Goncalo R. Abecasis, David Goltzman, Celia M. T. Greenwood, Claudia Langenberg, Aris Baras, Aris N. Economides, Manuel A. R. Ferreira, Sarah Hatsell, Claes Ohlsson, J. Brent Richards, Luca A. Lotta
Summary: This study leveraged rare coding variants and common alleles to identify therapeutic targets for osteoporosis. A large-scale multiancestry exome-wide association study identified 19 genes with rare coding alleles associated with bone mineral density. Integration of proteomics evidence and CRISPR-Cas9 editing highlighted CD109 as a gene associated with higher bone density.
Article
Business
Annika Wambsganss, Stefanie Broering, Soren Salomo, Nathalie Sick
Summary: Novel technologies, like fiber optics and printed electronics, are increasingly emerging at the intersection of unrelated technology areas. This presents both societal relevance and challenges for firms' technology strategies as they have to integrate and decide their engagement in the converging technology system, including the development of specialized or design knowledge.
JOURNAL OF PRODUCT INNOVATION MANAGEMENT
(2023)
Article
Oncology
Zhiqiang Tian, Xiaojuan Hou, Wenting Liu, Changchun Shao, Lu Gao, Jinghua Jiang, Li Zhang, Zhipeng Han, Lixin Wei
Summary: The study demonstrates the potential of targeting the CCL2/CCR2 and CXCLs/CXCR2 axes for the treatment of HCC. Blocking these axes enhances the anti-tumor effect of TACE treatment and overcomes TACE resistance in HCC.
CANCER CELL INTERNATIONAL
(2022)
Review
Biochemistry & Molecular Biology
Apostolos C. Agrafiotis, Mariana Brandao, Thierry Berghmans, Valerie Durieux, Christiane Jungels
Summary: This review investigates the efficacy of immune checkpoint inhibitors (ICI) in thymic epithelial tumors (TET). The results suggest that ICI could be a therapeutic option for unresectable TET, with variability in overall response rate, progression-free survival, and overall survival. Targeted therapies and tumor microenvironments (TME) elements that predict ICI efficacy were also assessed.
Article
Clinical Neurology
Julia A. Gillard, Siobhan Gormley, Kirsty Griffiths, Caitlin Hitchcock, Tim Dalgleish, Jason Stretton
Summary: The research shows that the risk of depressive relapse and recurrence is associated with perceptions of low social status, particularly among individuals with a self-reported history of mental health difficulties. Furthermore, enduring perceptions of low social status were found in remitted depressed individuals, indicating a potential vulnerability to future depressive episodes.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Review
Oncology
Amrita Singh, Sudhanshu Mishra, Saurabh Sharma, Smriti Ojha, Sunil Yagnik, Sudhi Pandey
Summary: One of the most important health problems in the world today is cancer. According to the World Health Organization (WHO), it causes 8.9 million deaths annually. Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death globally and the fifth most common type of cancer. Patients with liver disease and chronic hepatitis B and C are more susceptible to developing HCC. Traditional cancer therapies have limited efficacy due to multi-drug resistance, high clearance rates, and suboptimal drug distribution. Therefore, innovative drug molecules targeting liver cancer cells are needed to improve treatment outcomes.
CURRENT CANCER DRUG TARGETS
(2023)
Review
Biochemistry & Molecular Biology
Victoria Fernandez-Garcia, Silvia Gonzalez-Ramos, Paloma Martin-Sanz, Jose M. Laparra, Lisardo Bosca
Summary: Immunonutrition is a promising field in modern medicine that aims to improve immune system functioning and individual immunity. NOD1, a member of innate immunity receptors, has been associated with various pathologies and could be a valuable target for research in immunonutrition. Understanding the cellular and molecular mechanisms modulating the immune system and involving NOD1 activation is crucial for developing specific and personalized nutrition strategies in conjunction with surgical or pharmacological treatments.
Article
Radiology, Nuclear Medicine & Medical Imaging
Sebastian K. Chung, Daniela Burnes Vargas, Christopher S. Chandler, Sumudu Katugampola, Darren R. Veach, Michael R. McDevitt, Shin H. Seo, Brett A. Vaughn, Sara S. Rinne, Blesida Punzalan, Mitesh Patel, Hong Xu, Hong-Fen Guo, Pat B. Zanzonico, Sebastien Monette, Guangbin Yang, Ouathek Ouerfelli, Garrett M. Nash, Andrea Cercek, Edward K. Fung, Roger W. Howell, Steven M. Larson, Sarah M. Cheal, Nai-Kong V. Cheung
Summary: This study reports the use of human epidermal growth factor receptor 2 (HER2) Ac-225-pretargeted radioimmunotherapy (PRIT) to treat a mouse model of epithelial ovarian cancer (EOC). The results showed significantly prolonged survival and histologic cures with minimal toxicity in the treated group.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Kyle Concannon, Benjamin B. Morris, Carl M. Gay, Lauren A. Byers
Summary: Targeted therapy and immunotherapy have revolutionized cancer treatment, but cancer's ability to evade the immune system remains a major obstacle. DNA-damage response inhibitors (DDRis) have shown potential in enhancing anti-tumor immune responses, especially in tumors with genetic defects in DNA repair genes. This review explores the molecular consequences of targeted DDR inhibition, as well as the rationale and strategies for combining DDRis with immunotherapy for better tumor control. Biomarkers for patient selection and promising new immunotherapy approaches are also discussed.
Article
Oncology
Rebecca S. Kristeleit, Yvette Drew, Amit M. Oza, Susan M. Domchek, Susana Banerjee, Rosalind M. Glasspool, Judith Balmana, Lee-may Chen, Manish R. Patel, Howard A. Burris, Tamar Safra, Jennifer Borrow, Kevin K. Lin, Sandra Goble, Lara Maloney, Ronnie Shapira-Frommer
Summary: This study evaluated the efficacy and safety of oral rucaparib monotherapy in heavily pretreated patients with ovarian cancer. The results showed that rucaparib had robust antitumour activity and a good safety profile in patients who had received multiple prior chemotherapies.
BRITISH JOURNAL OF CANCER
(2023)